Vakona develops an antibiotic-free treatment for inflammatory acne using a natural bacterial enzyme that degrades bacterial biofilm. This approach targets the root cause of acne by effectively disrupting the biofilm formation that contributes to inflammation and infection.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inflammatory acne is often treated with antibiotics, which can lead to antibiotic resistance and disrupt the skin's natural microbiome. Current treatments may not effectively target the bacterial biofilms that contribute to inflammation and infection in acne.
Solution
Vakona is developing an antibiotic-free treatment for inflammatory acne that utilizes a natural bacterial enzyme to degrade bacterial biofilms. This approach addresses the root cause of acne by disrupting the biofilm formation that fosters inflammation and infection. By targeting the biofilm, Vakona's treatment aims to provide a more sustainable and effective solution for managing inflammatory acne without the risks associated with antibiotic use. The treatment seeks to restore balance to the skin's microbiome while reducing inflammation and promoting healing.
Target Audience
The primary target audience includes individuals suffering from inflammatory acne and dermatologists seeking alternative, antibiotic-free treatment options.
Features
- Utilizes a natural bacterial enzyme to degrade bacterial biofilms.
- Offers an antibiotic-free approach to acne treatment, reducing the risk of antibiotic resistance.
- Targets the root cause of acne by disrupting biofilm formation.
- Aims to reduce inflammation and promote healing.